Prescribing a medication such as naloxone provides doctors and pharmacists with the opportunity to talk about the risks of opioids with their patients.
In the Medical Journal of Australia, Painaustralia’s CEO Carol Bennett said it is also important for health professionals to address the stigma that can be associated with naloxone.
Ms Bennett said that when doctors and pharmacists talk about naloxone, they needed to be clear about the rationale for the medication, and the patient needed to understand its benefits.
The Australian Government currently has a Take-Home Naloxone Pilot that is running until 30 June 2021. Naloxone is a drug that can temporarily reverse the effects of an opioid overdose or adverse reaction.
The pilot is for:
people who are at risk of an opioid overdose or adverse reaction, their carers, friends and family members
approved providers such as community pharmacists, dispensing doctors and hospital pharmacists